

Chiara Pisciotta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4239189/publications.pdf>

Version: 2024-02-01

56
papers

1,750
citations

279798
23
h-index

289244
40
g-index

58
all docs

58
docs citations

58
times ranked

2444
citing authors

#	ARTICLE	IF	CITATIONS
1	Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. <i>Lancet Neurology</i> , The, 2011, 10, 320-328.	10.2	222
2	New developments in Charcot-Marie-Tooth neuropathy and related diseases. <i>Current Opinion in Neurology</i> , 2017, 30, 471-480.	3.6	145
3	Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease. <i>Brain</i> , 2009, 132, 2350-2355.	7.6	115
4	Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes. <i>Nature Genetics</i> , 2020, 52, 473-481.	21.4	97
5	Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability. <i>Neurogenetics</i> , 2011, 12, 33-39.	1.4	84
6	Charcot-Marie-Tooth disease: frequency of genetic subtypes in a Southern Italy population. <i>Journal of the Peripheral Nervous System</i> , 2014, 19, 292-298.	3.1	64
7	Nerve conduction velocity in <sc>CMT</sc> 1A: what else can we tell?. <i>European Journal of Neurology</i> , 2016, 23, 1566-1571.	3.3	45
8	Neuropathy. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 148, 653-665.	1.8	45
9	Cross-sectional analysis of a large cohort with X-linked Charcot-Marie-Tooth disease (CMTX1). <i>Neurology</i> , 2017, 89, 927-935.	1.1	44
10	Novel mutations in <i>dystonin</i> provide clues to the pathomechanisms of HSAN-VI. <i>Neurology</i> , 2017, 88, 2132-2140.	1.1	41
11	Absence of Dystrophin Related Protein-2 disrupts Cajal bands in a patient with Charcot-Marie-Tooth disease. <i>Neuromuscular Disorders</i> , 2015, 25, 786-793.	0.6	40
12	Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study. <i>Brain</i> , 2020, 143, 3589-3602.	7.6	39
13	A multicenter retrospective study of charcot-Marie-Tooth disease type 4B (CMT4B) associated with mutations in myotubularin-related proteins (MTMRs). <i>Annals of Neurology</i> , 2019, 86, 55-67.	5.3	35
14	Charcot-Marie-Tooth disease. <i>Neurology</i> , 2015, 85, 1202-1208.	1.1	33
15	Small-fiber involvement in spinobulbar muscular atrophy (Kennedy's disease). <i>Muscle and Nerve</i> , 2007, 36, 816-820.	2.2	31
16	Electrophysiological characterisation in hereditary spastic paraplegia type 5. <i>Clinical Neurophysiology</i> , 2011, 122, 819-822.	1.5	31
17	Small nerve fiber involvement in CMT1A. <i>Neurology</i> , 2015, 84, 407-414.	1.1	30
18	Expanding the spectrum of genes responsible for hereditary motor neuropathies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1171-1179.	1.9	30

#	ARTICLE	IF	CITATIONS
19	A longitudinal study of CMT1A using Rasch analysis based CMT neuropathy and examination scores. <i>Neurology</i> , 2020, 94, e884-e896.	1.1	29
20	Different nerve ultrasound patterns in charcotâ€œmarieâ€œtooth types and hereditary neuropathy with liability to pressure palsies. <i>Muscle and Nerve</i> , 2018, 57, E18-E23.	2.2	28
21	A new Italian FHM2 family: Clinical aspects and functional analysis of the disease-associated mutation. <i>Cephalalgia</i> , 2011, 31, 808-819.	3.9	27
22	Novel outcome measures for Charcotâ€œMarieâ€œTooth disease: validation and reliability of the 6â€œmin walk test and StepWatch [®] Activity Monitor and identification of the walking features related to higher quality of life. <i>European Journal of Neurology</i> , 2016, 23, 1343-1350.	3.3	26
23	Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients. <i>Neuromuscular Disorders</i> , 2014, 24, 1003-1017.	0.6	25
24	Altered TDP-43â€œdependent splicing in HSPB8â€œrelated distal hereditary motor neuropathy and myofibrillar myopathy. <i>European Journal of Neurology</i> , 2018, 25, 154-163.	3.3	24
25	Short-latency afferent inhibition in patients with Parkinsonâ€™s disease and freezing of gait. <i>Journal of Neural Transmission</i> , 2015, 122, 1533-1540.	2.8	22
26	Electrophysiological characterization of adult-onset Niemannâ€œPick type C disease. <i>Journal of the Neurological Sciences</i> , 2015, 348, 262-265.	0.6	22
27	Challenges in Treating Charcot-Marie-Tooth Disease and Related Neuropathies: Current Management and Future Perspectives. <i>Brain Sciences</i> , 2021, 11, 1447.	2.3	22
28	Reduced neurofilament expression in cutaneous nerve fibers of patients with CMT2E. <i>Neurology</i> , 2015, 85, 228-234.	1.1	21
29	Autonomic nervous system involvement in a new CMT2B family. <i>Journal of the Peripheral Nervous System</i> , 2012, 17, 361-364.	3.1	20
30	Postural instability in Charcot-Marie-Tooth 1A disease. <i>Gait and Posture</i> , 2016, 49, 353-357.	1.4	20
31	Charcot-Marie-Tooth Type 2B: A New Phenotype Associated with a Novel RAB7A Mutation and Inhibited EGFR Degradation. <i>Cells</i> , 2020, 9, 1028.	4.1	20
32	Hirayamaâ€™s disease: an Italian single center experience and review of the literature. <i>Quantitative Imaging in Medicine and Surgery</i> , 2016, 6, 364-373.	2.0	20
33	Autoimmune Autonomic Ganglionopathy. <i>Archives of Neurology</i> , 2011, 68, 504.	4.5	19
34	Somatosensory Temporal Discrimination Threshold Is Increased in Patients with Cerebellar Atrophy. <i>Cerebellum</i> , 2013, 12, 456-459.	2.5	19
35	GDAP1 mutations in Italian axonal Charcotâ€œMarieâ€œTooth patients: Phenotypic features and clinical course. <i>Neuromuscular Disorders</i> , 2016, 26, 26-32.	0.6	18
36	PFN2 and GAMT as common molecular determinants of axonal Charcot-Marie-Tooth disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 870-878.	1.9	16

#	ARTICLE	IF	CITATIONS
37	Motor performance deterioration accelerates after 50 years of age in Charcot-Marie-Tooth type 1A patients. <i>European Journal of Neurology</i> , 2018, 25, 301-306.	3.3	16
38	Updated review of therapeutic strategies for Charcot-Marie-Tooth disease and related neuropathies. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 701-713.	2.8	16
39	Case of acute motor conduction block neuropathy (AMCBN). <i>Muscle and Nerve</i> , 2009, 39, 224-226.	2.2	15
40	Influence of comorbidities on the phenotype of patients affected by Charcot-Marie-Tooth neuropathy type 1A. <i>Neuromuscular Disorders</i> , 2013, 23, 902-906.	0.6	15
41	Early onset Charcot-Marie-Tooth neuropathy type <scp>2A</scp> and severe developmental delay: expanding the clinical phenotype of <scp>MFN2</scp>-related neuropathy. <i>Journal of the Peripheral Nervous System</i> , 2015, 20, 415-418.	3.1	14
42	A novel autosomal dominant <i>GDAP1</i> mutation in an Italian CMT2 family. <i>Journal of the Peripheral Nervous System</i> , 2012, 17, 351-355.	3.1	13
43	Pregnancy in Charcot-Marie-Tooth disease. <i>Neurology</i> , 2020, 95, e3180-e3189.	1.1	11
44	Electrophysiological comparison between males and females in HNPP. <i>Neurological Sciences</i> , 2013, 34, 1429-1432.	1.9	10
45	Autophagy and Lysosomal Functionality in CMT2B Fibroblasts Carrying the RAB7K126R Mutation. <i>Cells</i> , 2022, 11, 496.	4.1	10
46	Two families with novel <i>PMP22</i> point mutations: genotype-phenotype correlation. <i>Journal of the Peripheral Nervous System</i> , 2009, 14, 208-212.	3.1	9
47	Nine-year case history of monofocal motor neuropathy. <i>Muscle and Nerve</i> , 2008, 38, 927-929.	2.2	8
48	A novel family with axonal Charcot-Marie-Tooth disease caused by a mutation in the <i>EGR2</i> gene. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 219-223.	3.1	7
49	Myelin protein zero gene dose dependent axonal ion-channel dysfunction in a family with Charcot-Marie-Tooth disease. <i>Clinical Neurophysiology</i> , 2020, 131, 2440-2451.	1.5	7
50	<i>DNAJB2</i>-related Charcot-Marie-Tooth disease type 2: Pathomechanism insights and phenotypic spectrum widening. <i>European Journal of Neurology</i> , 2022, 29, 2056-2065.	3.3	7
51	Are novel outcome measures for Charcot-Marie-Tooth disease sensitive to change? The 6-minute walk test and StepWatch [®] Activity Monitor in a 12-month longitudinal study. <i>Neuromuscular Disorders</i> , 2019, 29, 310-316.	0.6	6
52	Validation of the Italian version of the <scp>Charcot-Marie-Tooth</scp> disease Pediatric Scale. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 138-142.	3.1	5
53	Insights into the pathogenesis of ATP1A1-related CMT disease using patient-specific iPSCs. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 330-339.	3.1	4
54	Validation of the Italian version of the <scp>Charcot-Marie-Tooth</scp> Health Index. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 292-296.	3.1	3

#	ARTICLE	IF	CITATIONS
55	Thermosensitive hereditary neuropathy with liability to pressure palsy. Muscle and Nerve, 2011, 43, 448-449.	2.2	2
56	A case of congenital cataracts, facial dysmorphisms, neuropathy, and hyperkinetic movement disorder. Movement Disorders, 2013, 28, 559-560.	3.9	1